Amy DuRoss, CEO of Vineti, on software and logistics for cell and gene therapy.

Ep88: Amy DuRoss on software and logistics for cell and gene therapy

Emily Leproust, co-founder and CEO of Twist Bioscience, on DNA Synthesis at Scale

Ep89: Emily Leproust on DNA Synthesis at Scale

Ken Song, CEO of RayzeBio, on targeted radiopharmaceuticals for cancer.

Ep103: Ken Song on Targeted Radiopharmaceuticals for Cancer

Shelley Force Aldred and Nathan Trinklein, co-founders of Rondo Therapeutics, on the opportunity with bispecific antibodies for cancer.

Ep151: Shelley Force Aldred and Nathan Trinklein on Bispecific Antibodies for Cancer

Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.

Ep152: Jens Eckstein on Investing in Healthy Aging

Sean McClain, CEO of Absci, on using AI to speed up biologic drug discovery.

Ep162: Sean McClain on AI for Biologic Drug Discovery

Sarah Boyce, CEO of San Diego-based Avidity Biosciences, on RNA medicines for rare muscle diseases.

Ep163: Sarah Boyce on RNA Medicines for Muscle Diseases

Chris Garcia, professor at Stanford University and co-founder of several biotech startups, on using protein engineering to advance new treatments for cancer and autoimmune diseases.

Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity

Alnylam Pharmaceuticals chief scientific officer Kevin Fitzgerald on the past, present & future of RNA interference medicines.

Ep169: Kevin Fitzgerald on the Past & Future of RNAi Medicines

David Schenkein, general partner at GV, on investing in the future of biotech.

Ep170: David Schenkein on Investing in the Future of Biotech

Ram Aiyar, CEO of Cambridge, Mass.-based Korro Bio, on RNA editing medicines.

Ep171: Ram Aiyar on RNA Editing Medicines

Najat Khan, chief R&D and chief commercial officer of Recursion, on using technology to improve drug discovery.

Ep174: Najat Khan on the TechBio Movement

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

Ep175: Andy Scharenberg on in vivo CAR-T cell therapies

David Roblin, CEO of London-based Relation Therapeutics, on building a techbio discovery company.

Ep176: David Roblin on Building a TechBio Company

Kevin Parker, CEO of Cartography Biosciences, on finding new cancer drug targets.

Ep177: Kevin Parker on Finding Cancer Drug Targets

Peyton Greenside, co-founder and CEO of BigHat Biosciences, on machine-learning guided biologic drug discovery.

Ep178: Peyton Greenside on ML-Guided Biologics Discovery

Marea Therapeutics CEO Josh Lehrer and CSO Ethan Weiss on a new angle of attack against cardiovascular disease and diabetes.

Ep179: Ethan Weiss & Josh Lehrer on a New Idea for Cardiovascular Disease & Diabetes

John Rinn, professor at the University of Colorado and co-founder of Lincswitch Therapeutics, on exploring long non-coding RNA.

Ep180: John Rinn on Discovering Drugs Based on Long Non-Coding RNA

Claire Mazumdar, CEO of Boston-based Bicara Therapeutics, on developing a bifunctional antibody for head and neck cancer.

Ep181: Claire Mazumdar on a Two-Pronged Attack Against Cancer

Andy Rachleff and Yung Lie, board chair and CEO of Damon Runyon Cancer Research Foundation, on creative ways to support science amid budget cuts.

Ep182: Andy Rachleff & Yung Lie on Creative Ways to Back Science

Sabah Oney, CEO of Philadelphia and San Francisco-based Dispatch Biotherapeutics, on engineering CAR-T cells that can kill solid tumors.

Ep183: Sabah Oney on CAR-T Cells Against Solid Tumors

Jen Adair, professor and associate director of the Horae Gene Therapy Center at the University of Massachusetts Chan Medical School, on creating more affordable and accessible cell and gene therapies.

Ep184: Jen Adair on Affordable, Accessible Gene & Cell Therapies

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

Ep185: Dr. Lachelle Weeks on Predicting Leukemia Risk At Scale

Bruce Levine, a CAR-T cell therapy researcher at the University of Pennsylvania, and Mags McCarthy, a country music star, discuss their new song about science and hope for cancer patients. 

Ep186: Bruce Levine & Mags McCarthy on a Song About Science and Hope

Eric Fischer, a professor at Dana-Farber Cancer Institute, on creating a new class medicines -- targeted protein degraders.

Ep187: Eric Fischer on Creating a New Class of Medicines

Art Krieg, founder and CEO of Zola Therapeutics, on developing innate immune system activators for cancer.

Ep188: Art Krieg on Innate Immune System Activators for Cancer

Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics, on reinventing drug discovery with AI.

Ep189: Marc Tessier-Lavigne on Reinventing Drug Discovery with AI

Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Ep190: Neil Kumar on Building a Rare Disease Drug Company

Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD). 

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Bob Nelsen of ARCH Venture Partners on long-term trends in biotech investing.

Ep87: Bob Nelsen of ARCH Venture Partners on Biotech Investing

"The Long Run"

Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous. 

Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.

The Long Run with Luke Timmerman

Popular tracks